Roche’s Ventana PD-L1 (SP142) Receives FDA’s Approval for Identifying Triple-Negative Breast Cancer (TNBC) as CDx

 Roche’s Ventana PD-L1 (SP142) Receives FDA’s Approval for Identifying Triple-Negative Breast Cancer (TNBC) as CDx

Roche’s Ventana PD-L1 (SP142) Receives FDA’s Approval for Identifying Triple-Negative Breast Cancer (TNBC) as CDx

Shots:

  • The approval is based on IMpassion130 study assessing Tecentriq + Abraxane vs PBO + Abraxane in patients with advanced or mTNBC with no prior therapy
  • The Ventana PD-L1 (SP142) assay was used in Roche’s Tecentriq clinical trials to stratify patients and enhances the visual contrast of tumor-infiltrating immune cell staining
  • The Ventana PD-L1 (SP142) assay is a companion diagnostic, performs specific staining of tumor cells with the use of OptiView DAB IHC detection kit with OptiView amplification kit and has received FDA’s Approval for UC & NSCLC with Tecentriq

Click here to read full press release/ article | Ref: Roche | Image: SOM

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post